CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT05722418. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Study identification
- NCT ID
- NCT05722418
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Caribou Biosciences, Inc.
- Industry
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
- CB-011 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 5, 2023
- Primary completion
- Nov 30, 2027
- Completion
- Nov 30, 2027
- Last update posted
- Sep 24, 2025
2023 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | Recruiting |
| CU Anschutz Medical Campus, Anshutz Cancer Pavillion | Aurora | Colorado | 80045 | Recruiting |
| Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics | Miami | Florida | 33136 | Recruiting |
| University of Kentucky/ Markey Cancer Center | Lexington | Kentucky | 40536 | Recruiting |
| Hackensack Meridian John Theurer Cancer Center | Hackensack | New Jersey | 07601 | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | Recruiting |
| Duke University Health System (DUHS) | Durham | North Carolina | 27705 | Recruiting |
| Oncology Hematology Care, Inc | Cincinnati | Ohio | 45236 | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | Recruiting |
| Virginia Commonwealth University | Richmond | Virginia | 23235 | Recruiting |
| Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05722418, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05722418 live on ClinicalTrials.gov.